| A feasibility study testing four hypotheses with phase II outcomes in advanced colorectal cancer (MRC FOCUS3): a model for randomised controlled trials in the era of personalised medicine? |
Maughan TS, Meade AM, Adams RA, Richman SD, Butler R, Fisher D, Wilson RH, Jasani B, Taylor GR, Williams GT, Sampson JR, Seymour MT, Nichols LL, Kenny SL, Nelson A, Sampson CM, Hodgkinson E, Bridgewater JA, Furniss DL, Roy R, Pope MJ, Pope JK, Parmar M, Quirke P, Kaplan R. |
2014 |
Br J Cancer |
Link
|
| Somatic cancer genetics in the UK: real-world data from phase I of the Cancer Research UK Stratified Medicine Programme. |
Lindsay CR, Shaw EC, Blackhall F, Blyth KG, Brenton JD, Chaturvedi A, Clarke N, Dick C, Evans TRJ, Hall G, Hanby AM, Harrison DJ, Johnston SRD, Mason MD, Morton D, Newton-Bishop J, Nicholson AG, Oien KA, Popat S, Rassl D, Sharpe R, Taniere P, Walker I, Wallace WA, West NP, Butler R, Gonzalez de Castro D, Griffiths M, Johnson PWM. |
2018 |
ESMO Open |
Link
|
| Integrative analysis of the microRNA-mRNA response to radiochemotherapy in primary head and neck squamous cell carcinoma cells. |
Summerer I, Hess J, Pitea A, Unger K, Hieber L, Selmansberger M, Lauber K, Zitzelsberger H. |
2015 |
BMC Genomics |
Link
|
| Changes in circulating microRNAs after radiochemotherapy in head and neck cancer patients. |
Summerer I, Niyazi M, Unger K, Pitea A, Zangen V, Hess J, Atkinson MJ, Belka C, Moertl S, Zitzelsberger H. |
2013 |
Radiat Oncol |
Link
|
| Analysis of Fascin-1 in Relation to Gleason Risk Classification and Nuclear ETS-Related Gene Status of Human Prostate Carcinomas: An Immunohistochemical Study of Clinically Annotated Tumours From the Wales Cancer Bank. |
Jefferies MT, Pope CS, Kynaston HG, Clarke AR, Martin RM, Adams JC. |
2017 |
Biomark Cancer |
Link
|
| Long-Term Culture of Intestinal Cell Progenitors: An Overview of Their Development, Application, and Associated Technologies. |
Hollins AJ, Parry L. |
2016 |
Curr Pathobiol Rep |
Link
|
| Prostate stromal cell proteomics analysis discriminates normal from tumour reactive stromal phenotypes. |
Webber JP, Spary LK, Mason MD, Tabi Z, Brewis IA, Clayton A. |
2016 |
Oncotarget |
Link
|
| Tumor stroma-derived factors skew monocyte to dendritic cell differentiation toward a suppressive CD14<sup>+</sup> PD-L1<sup>+</sup> phenotype in prostate cancer. |
Spary LK, Salimu J, Webber JP, Clayton A, Mason MD, Tabi Z. |
2014 |
Oncoimmunology |
Link
|
| Inhibition of EGFR, HER2, and HER3 signalling in patients with colorectal cancer wild-type for BRAF, PIK3CA, KRAS, and NRAS (FOCUS4-D): a phase 2-3 randomised trial. |
Adams R, Brown E, Brown L, Butler R, Falk S, Fisher D, Kaplan R, Quirke P, Richman S, Samuel L, Seligmann J, Seymour M, Shiu KK, Wasan H, Wilson R, Maughan T, FOCUS4 Trial Investigators. |
2018 |
Lancet Gastroenterol Hepatol |
Link
|
| 3D imaging of colorectal cancer organoids identifies responses to Tankyrase inhibitors. |
Badder LM, Hollins AJ, Herpers B, Yan K, Ewan KB, Thomas M, Shone JR, Badder DA, Naven M, Ashelford KE, Hargest R, Clarke AR, Esdar C, Buchstaller HP, Treherne JM, Boj S, Ramezanpour B, Wienke D, Price LS, Shaw PH, Dale TC. |
2020 |
PLoS One |
Link
|
| Evaluation of CD46 re-targeted adenoviral vectors for clinical ovarian cancer intraperitoneal therapy. |
Hulin-Curtis SL, Uusi-Kerttula H, Jones R, Hanna L, Chester JD, Parker AL. |
2016 |
Cancer Gene Ther |
Link
|
| STEAP2 Knockdown Reduces the Invasive Potential of Prostate Cancer Cells. |
Burnell SEA, Spencer-Harty S, Howarth S, Bodger O, Kynaston H, Morgan C, Doak SH. |
2018 |
Sci Rep |
Link
|
| AR mRNA stability is increased with AR-antagonist resistance via 3'UTR variants. |
Dart DA, Ashelford K, Jiang WG. |
2020 |
Endocr Connect |
Link
|
| Utilisation of the STEAP protein family in a diagnostic setting may provide a more comprehensive prognosis of prostate cancer. |
Burnell SEA, Spencer-Harty S, Howarth S, Bodger O, Kynaston H, Morgan C, Doak SH. |
2019 |
PLoS One |
Link
|
| Impairment of cell adhesion and migration by inhibition of protein disulphide isomerases in three breast cancer cell lines. |
Young HS, McGowan LM, Jepson KA, Adams JC. |
2020 |
Biosci Rep |
Link
|
| Importance of activated leukocyte cell adhesion molecule (ALCAM) in prostate cancer progression and metastatic dissemination. |
Sanders AJ, Owen S, Morgan LD, Ruge F, Collins RJ, Ye L, Mason MD, Jiang WG. |
2019 |
Oncotarget |
Link
|
| Macrophage Plasticity and Function in the Lung Tumour Microenvironment Revealed in 3D Heterotypic Spheroid and Explant Models. |
Evans L, Milward K, Attanoos R, Clayton A, Errington R, Tabi Z. |
2021 |
Biomedicines |
Link
|
| Whole blood-based measurement of SARS-CoV-2-specific T cells reveals asymptomatic infection and vaccine immunogenicity in healthy subjects and patients with solid-organ cancers. |
Scurr MJ, Zelek WM, Lippiatt G, Somerville M, Burnell SEA, Capitani L, Davies K, Lawton H, Tozer T, Rees T, Roberts K, Evans M, Jackson A, Young C, Fairclough L, Tighe P, Wills M, Westwell AD, Morgan BP, Gallimore A, Godkin A. |
2022 |
Immunology |
Link
|
| Accumulation of copy number alterations and clinical progression across advanced prostate cancer. |
Grist E, Friedrich S, Brawley C, Mendes L, Parry M, Ali A, Haran A, Hoyle A, Gilson C, Lall S, Zakka L, Bautista C, Landless A, Nowakowska K, Wingate A, Wetterskog D, Hasan AMM, Akato NB, Richmond M, Ishaq S, Matthews N, Hamid AA, Sweeney CJ, Sydes MR, Berney DM, Lise S, STAMPEDE investigators, Parmar MKB, Clarke NW, James ND, Cremaschi P, Brown LC, Attard G. |
2022 |
Genome Med |
Link
|
| Prediction models for hormone receptor status in female breast cancer do not extend to males: further evidence of sex-based disparity in breast cancer. |
Chatterji S, Niehues JM, van Treeck M, Loeffler CML, Saldanha OL, Veldhuizen GP, Cifci D, Carrero ZI, Abu-Eid R, Speirs V, Kather JN. |
2023 |
NPJ Breast Cancer |
Link
|